• Clinical Indications Overview
• Asthma
• COPD
• Cystic Fibrosis
• Eczema

Aerovance™ focuses exclusively on developing safe and effective breakthrough medicines for respiratory and allergic inflammatory diseases where current therapies do not provide adequate improvement in the patient's health and quality of life. By developing innovative therapies that target the underlying causes of difficult to treat diseases such as, moderate to severe asthma, severe eczema, cystic fibrosis and chronic obstructive pulmonary disease, Aerovance's goal is to offer patients effective maintenance therapies with improved safety benefits.

Asthma

Asthma affects approximately 17 million people in the United States and over 300 million worldwide. It is estimated that one out of every four people living with asthma is not adequately controlled on currently available medications. Asthma is a recurring condition in which environmental triggers (such as pollen, dust and cold air) cause the abnormal release of cytokines from T helper type 2 (Th2) immune cells. Specifically, the cytokines interleukin 4 (IL-4) and interleukin 13 (IL-13) cause inflammation and constriction of the airways. Th2 over-expression is believed to be one of the most important pathways in the pathology of asthma, particularly in patients living with severe, uncontrolled asthma.

Eczema

Eczema is a form of dermatitis, or inflammation of the upper layers of the skin that affects approximately 1-3% of adults worldwide. IL-4 and IL-13 are potent inflammatory mediators of allergic inflammation, critical in the development of severe eczema. Over 500,000 eczema patients in the U.S. are unable to effectively treat their flare-ups with currently available treatment options.   

Cystic Fibrosis

Cystic Fibrosis (CF) is a life-threatening, inherited genetic disease that primarily affects the respiratory and digestive systems. CF affects approximately 70,000 people worldwide with a median life expectancy of 35 years. CF causes the production of abnormally thick mucus secretions in the lungs and pancreas, leading to life-threatening lung infections and difficulty in digestion. Current therapies for patients and families living with cystic fibrosis are used both intermittently and chronically to minimize airway and intestinal obstruction and control life-threatening lung infections.  

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease and an umbrella term for a group of respiratory tract diseases that are characterized by airflow obstruction or limitation. COPD will rank fifth among medical conditions by 2020, and due to the debilitating nature of the condition, COPD will impose one of the greatest burdens on the healthcare system, affecting more than 200 million people worldwide. The most common cause of COPD is tobacco smoking, but COPD can also be caused by exposure to other airway irritants such as coal dust or solvents. COPD is a disease state characterized by airflow limitation that is usually progressive and not fully reversible.